团队现有博士后1名，博士生7名、硕士生3名，联合培养博士生两名。

研究方向：

研究组致力于血液肿瘤等恶性疾病的靶向和免疫治疗相关促降解新靶点发现和首创型靶向降解剂研发，目前主要研究方向包括：

1.   血液肿瘤等恶性疾病中致病蛋白促降解泛素化酶（E3）、去泛素化酶 (DUB) 及其配体的发现；

2.   克服血液肿瘤多种耐药、突变选择型降解新靶点及药物的发现；

3.   赋能CAR-T细胞治疗的免疫调节因子、小分子降解药物及免疫联合疗法开发。

本课题组常年招聘副研究员、助理研究员、博士后数名（免疫学及药理药化研究方向优先），欢迎博士生、硕士生、本科生报考和实习！

2023年夏，杨老师带学生做SITP项目~

2023年9月，第一个教师节~~团队又壮大啦~

2023年秋，课题组团建留影~~

2024年9月，第二个教师节留影~

课题组在研主持国家自然科学基金两项，课题组长入选主持上海领军人才（海外）项目，中国科学院青促会人才计划，安徽省 "百人计划” 青年项目，并主持前沿科学中心科技领军人才团队项目，同济大学“医学+X”交叉研究项目，参与国家重点研发项目等。

主持项目：

(1) 2026同济大学“医学+X”交叉研究项目，A+B (B负责人)，2026-01 至 2029-12, 总100万元, 在研，主持50万元

(2) 国家自然科学基金委员会，面上项目，82373937，针对继发性急性髓系白血病中JAK2-V617F突变体的促降解新靶点发现和机制研究，2024-01-01 至 2027-12-31, 48万元, 在研, 主持

(3) 国家自然科学基金委员会, 青年科学基金项目, 82104198, 针对弥漫大B细胞淋巴瘤中EZH2-Y641突变体选择性降解剂的发现及机制研究, 2022-01-01 至 2024-12-31, 30万元, 结题, 主持

(4) 中国科学院, 中国科学院基金项目, 2022453, 青年创新促进会会员-杨静, 2022-01 至 2025-12, 80万元, 结题, 主持

(5) 上海市委, 人才项目, 上海领军人才（海外）, 2022-09 至 2028-09, 120万元, 在研, 主持

(6) 安徽省委, 安徽省海外引才计划, 安徽省“百人计划“青年项目（安徽省海外引才计划青年项目）, 2022-06 至 2025-06, 30万元, 结题, 主持

(7) 教育部前沿科学中心，前沿科学中心科技领军人才团队项目，2023-08 至 2023-11, 15万元, 结题, 主持

泛素化靶向蛋白降解是有望突破传统抑制剂瓶颈的新策略。本课题组长期致力于复发难治性血液肿瘤治疗新靶点发现与首创型降解药物研发，主要原创成果包括：①发现针对JAK2等突变及组成型激活蛋白的首个促降解因子，并设计突变选择型降解剂；②鉴定克服FLT3-ITD等复杂耐药性的促降解因子，并优化首创型降解剂；③阐明难成药因子FOXP3等的促复发新机制，并发现促降解靶点及系列Treg清除剂。成果拓展了可降解蛋白组，为解决传统抑制剂耐药性与可及性问题提供新策略。以第一或通讯作者（含共同）发表Nat Chem Biol, Nat. Commun., Advanced Science（2025a, 2025b）, Leukemia (2022a, 2022b)，Signal Trans. Target. Ther.等研究论文20余篇，公布/实审国际国内专利6项（授权2项），受Nat Rev Drug Discov等专刊或亮点点评。

五年内部分代表性工作：

1.    Bowen Li*, Haoran Xu*, Wenjun Zhang, Jing Yang#. Disarming CAR-Tregs with a clinical-stage natural product to supercharge CAR-T therapy. Molecular Therapy Oncology. May 2026, 34, 201232

2.    Mingqi Hou*; Wenjun Zhang*; Ziping Qi*; Guiming Li*; Husheng Mei; Shuang Qi; Rui Jin; Yuedong Zhao; Xiaochen Tang; Bing Xiu; Xiaotong Chen; Yunshuo Zhao; Chen Hu; Changlin Qian; Xiuchun Li; Zhan Xu; Yongfei Chen; Chao Wu; Beilei Wang; Lejin Yan; Dan Li; Yushan Huang; Rui Liang; Aoli Wang; Jing Liu; Wenchao Wang; Bin Li; Jun Long; Ping Li; Aibin Liang#; Qingsong Liu#; Jing Yang#. Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs. Nature Communications. Mar. 2026, 17 (1), 3045. 

3.    Yajing Yang*, Bowen Li*, Jing Yang#. Therapeutic Targets and Strategies for Long COVID and Post-Viral Syndrome. Frontiers in Cellular and Infection Microbiology. Mar. 2026;16, 1820002 

4.    Yushan Huang*, Jun Long*, Changpeng Yang, Wang Lu, Husheng Mei, Wenbin Qian#, Jing Yang#, Aibin Liang#. Overcoming Challenges in CAR-T Therapy for Malignancies: Mechanisms and Strategies. Clinical and Translational Discovery. Feb. 2026;6:e70045. 

5.    Husheng Mei*, Wuqiang Wen*, Wenjun Zhang*, Shujing Zhang*, Ting Sun*, Guiming Li, Jing Zhang, Shuang Qi, Jie Zhou, Bing Li, Yunshuo Zhao, Xiaotong Chen, Bowen Li, Yiying Xue, Wang Lu, Yanli Sun, Jingyao Wang, Hengyue Shan, Shengzhe Zhang, Yushan Huang, Yisa Chen, Wenchao Wang, Qingsong Liu, Wenchao Lu, Li Tan, Yi Ding, Jianfei Fu, Jun Long, Lei Zhang, Baobing Zhao#, Aibin Liang#, Baishan Jiang#, Jing Yang#. Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias. Advanced Science. Dec. 2025, 13(7): e15127. 

6.    Linhui Cao*, Jing Yang*, Yuhang Liu, Xiaotong Chen, Yufang Shi, Yunshuo Zhao, Yong Zhang, Jian Chen, Bowen Li, Wuqiang Wen, Lu Chen, Bo Peng, Lu Huang, Yanli Sun, Lixin Zhou, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Zhixiang Guo, Jing Xing, Guangya Zhu, Yazhou Wang, Baishan Jiang, Jing Lu, Kehao Zhao#, Wenchao Lu#. Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity. Advanced Science. Dec. 2025, 12(48): e03277.

7. Sun, Yanli*; Zhang, Fengying*; Zhou, Lixin*; Feng, Yixuan; Huang, Lu; Lu, Qiuxian; Yuan, Xin; Hou, Wenqing; Liu, Biwei; Guo, Zhixiang; Chen, Lu; Peng, Bo; Yin, Xianzhen; Zhang, Yiwen; Yang, Jing#; Chen, Nan#; Lu, Wenchao#. Discovery of Potent, Allosteric GSTO1 Covalent Inhibitors with a New Binding Mode. Journal of Medicinal Chemistry. Nov. 2025, 68(22): 24075-24093 

8.    Yiying Xue*, Bing Xiu*, Muye Yang*, Yanwei Zhang*, Changpeng Yang, Lele Zhang, Yilv Yan, Xiu Luo, Yushan Huang, Husheng Mei, Guiming Li, Lixin Zhou, Yisa Chen, Wenjun Zhang, Changlin Qian, Peng Zhang, Juan Liu#, Aibin Liang#, Yu Zeng#, Jing Yang#. Ubiquitin-Specific Protease 7-Mediated Stabilization of Discoidin Domain Receptor 1 Drives Progression of TP53-Mutant Cancers. Journal of Biological Chemistry. 2025 Sep;301(9):110515.

9.    Husheng Mei*, Hong Wu*, Jing Yang*, Bin Zhou*, Aoli Wang, Chen Hu, Shuang Qi, Zongru Jiang, Fengming Zou, Beilei Wang, Feiyang Liu, Yongfei Chen, Zuowei Wang, Wenchao Wang, Jing Liu, Qingsong Liu. Discovery of IHMT-337 as a potent irreversible inhibitor targeting novel noncanonical role of EZH2 for triple-negative breast cancer. Signal Transduct. Target Ther., 8 (1), 18, Jan. 2023.

10.    Jing Yang*, Ellen L. Weisberg*, Shuang Qi*, Wei Ni, Husheng Mei, Zuowei Wang, Chengcheng Meng, Shengzhe Zhang, Mingqi Hou, Ziping Qi, Aoli Wang, Yunyun Jiang, Zongru Jiang, Tao Huang, Qingwang Liu, Robert S. Magin, Laura Doherty, Wenchao Wang, Jing Liu, Sara J. Buhrlage, Qingsong Liu, James D. Griffin. Inhibition of deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia. 36, pages 1048-1057, Apr. 2022

11.    Jing Yang*, Ellen L. Weisberg*, Xiaoxi Liu*, Robert Magin, Wai Cheung Chan, Bin Hu, Nathan Schauer, Shengzhe Zhang, Ilaria Lamberto, Laura Doherty, Chengcheng Meng, Martin Sattler, Lucia Cabal-Hierro, Eric Winer, Richard Stone, Jarrod Marto, James Griffin, and Sara Buhrlage. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia. 36, pages 210-220, Jan. 2022

12.     Jing Yang*, Ping Wei*, Joseph Barbi, Qianru Huang, Evan Yang, Yakun Bai, Jia Nie, Yanhang Gao, Jinhui Tao, Ying Lu, Chichu Xie, Xiaoxia Hou, Jiazi Ren, Xingmei Wu, Jian Meng, Ying Zhang, Juan Fu, Wei Kou, Yayi Gao, Zuojia Chen, Rui Liang, Andy Tsun, Dan Li, Wenzhi Guo, Shuijun Zhang, Song-Guo Zheng, Junqi Niu, Paul Galardy, Xuemei Tong, Guochao Shi, Huabin Li, Fan Pan and Bin Li. The deubiquitinase USP44 promotes Treg function during inflammation by preventing FOXP3 degradation. EMBO Reports. 21 (9), e50308, Jul. 2020

13.     Jing Yang*, Chengcheng Meng*, Ellen L. Weisberg*, Ilaria Lamberto, Martin Sattler, Nathanael S. Gray, Sara J. Buhrlage, James D. Griffin. Inhibition of the deubiquitinase USP10 induces degradation of SYK. British Journal of Cancer, 122 (8), 1175-1184. Feb. 2020

14.    Guiming Li*, Wenjun Zhang#, Jing Yang#. Time - the fourth dimension of immune cells. MedComm. 2024 Aug 4;5(8):e682.  

15.    Yiying Xue*, Husheng Mei*, Yisa Chen, James D. Griffin, Qingsong Liu#, Ellen Weisberg#, Jing Yang#. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-COV-2. MedComm. May 2023; 4(3):e254. 

16.    Yisa Chen, Yiying Xue, Jing Yang#. Gilteritinib: Repurposing of AXL-targeting kinase inhibitors against COVID-19. Journal of Medical Virology, Mar. 2023; 95(3):e28592. 

专利：

1. 知母皂苷AIII在制备CAR-T细胞疗法的疗效增强剂及克服耐药性产品中的应用 (CN121695159A)

发明人：杨静，张文君，李桂明，侯明琪

2. 靶向USP7 降解DDR1 蛋白降解剂及其制备方法和应用 (CN120504663A)

发明人：杨静, 梁爱斌, 周立昕, 修冰

3. 噻唑类化合物、去SUMO 和/或去泛素化酶抑制剂及其制备方法和应用 (ZL2024115692600)

发明人：杨静(YANG, Jing), 梁爱斌(LIANG, AIbin), 梅沪生(Mei,Husheng), 文武强(Wen Wuqiang)

 4. Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (Josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (Jak2). (AU2022317661B2, US20240335427A1, CA3224123A1, EP4377299A4, WO2023009982A1)

Sara Buhrlage, James Griffin, Ellen Weisberg, Jing Yang, Xiaoxi Liu, Robert Magin, Bin Hu, Wai Cheung Chan

 5. Use of Ubiquitination Pathway-related Factors in Regulating Function of T Helper Cell. 泛素化途径相关因子在调控辅助性T细胞功能中的应用。 (PCT/CN2015/084078) WO2016/011906A1

发明人：李斌 (LI, Bin), 杨静 (YANG, Jing), 韩磊 (HAN, Lei) ,林芳(LIN, Fang), 李孔晨 (LI, Kongchen), 李丹 (LI, Dan)

 6. 泛素化途径相关因子在调控调节性T细胞功能中的应用 （CN108144049A）

发明人：李斌; 杨静; 徐鹏; 李丹; 梁瑞